RASEF

Across TCGA pan-cancer cohorts, RASEF Mutation is linked to patient survival in 11 of 34 cancer types, making it a survival-associated RASEF data layer compared with 25 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher RASEF Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RASEF expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BRCA, ACC, and LUAD are the cancer types where RASEF Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.396	0.924	<.001	36	view →
ACC	DFS	Median	All	0.046	0.753	<.001	24	view →
LUAD	OS	Median	III,IV	0.223	0.677	.006	12	view →
UCEC	DFS	Median	All	0.964	0.618	.011	10	view →
KIRP	OS	Median	II,III,IV	0.188	0.771	.016	9	view →
SARC	DFS	Median	All	0.159	0.613	.015	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
HNSC	OS	Median	IV	0.102	0.733	<.001	6	view →
ESCA	OS	Median	II,III,IV	0.216	0.702	.014	6	view →
LUSC	OS	Median	All	0.196	0.724	.049	3	view →
SKCM	OS	Median	All	0.125	0.331	.005	2	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

RASEF–BRCA (OS)

Open the BRCA breakdown →